Watch Ticker

Trevi Therapeutics, Inc. Common Stock

Go to Trevi Therapeutics, Inc. Common Stock Website

$7.41

0.00 (0.00%)

Live

Previous Close

$7.41

Day Range

$0 - $0

Previous Day Range

$7.26 - $7.49

Market Cap

$911.9 million USD

Day Vol.

Previous Day Vol.

1.0 million

Currency

USD

Primary Exchange

Nasdaq

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary f...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Kaskela Law Llc - TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm

Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.

Related tickers: TRVI, STGW, AGIO.

Read Full Article

Delveinsight - Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

Related tickers: SNDX, PRTC, OTSKY, TRVI, SRPT, CTNM.

Read Full Article

Trending Tickers

Please sign in to view